Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis And Xuanwu Hospital Capital Medical University To Set Up Regeneration Lab

This article was originally published in PharmAsia News

Executive Summary

Sanofi-Aventis will cooperate with Xuanwu Hospital Capital Medical University to set up a regeneration laboratory to focus on research of the central nervous system, metabolic disorders and geriatric diseases. Since 2007, the company has established strategic partnerships with China's leading academic institutions. These include Tianjin Institute of Hematology and Blood Diseases Hospital, which comes under the Chinese Academy of Medical Sciences; and Shanghai Institute for Biological Sciences. Sanofi-Aventis disclosed that it is likely to launch a new oncology drug by the end of the year. The company's China operation currently prioritizes R&D and it will continue to build close partnerships with academic institutions. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel